S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

@article{Dekeyne2008S32006AN,
  title={S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models},
  author={Anne Dekeyne and Clotilde Mannoury la Cour and Alain P. Gobert and Mauricette Brocco and Françoise Lejeune and Florence Serres and Trevor Sharp and Annie Daszuta and Am{\'e}lie Soumier and Mariusz Papp and Jean Michel Rivet and Gunnar Flik and Thomas I.F.H. Cremers and Olivier Muller and Gilbert Lavielle and Mark J Millan},
  journal={Psychopharmacology},
  year={2008},
  volume={199},
  pages={549-568}
}
RationaleSerotonin (5-HT)2C receptors are implicated in the control of mood, and their blockade is of potential interest for the management of anxiodepressive states.ObjectivesHerein, we characterized the in vitro and in vivo pharmacological profile of the novel benzourea derivative, S32006.Materials and methodsStandard cellular, electrophysiological, neurochemical, and behavioral procedures were used.ResultsS32006 displayed high affinity for human (h)5-HT2C and h5-HT2B receptors (pKis, 8.4 and… 

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization

S32212 behaves as an inverse agonist at h5-HT2C receptors and as an antagonist at human α2-adrenoceptors (and h5/HT2A receptors), potentially relevant to the treatment of depression.

S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

The present studies characterized the functional profile of S32212, a combined serotonin (5-HT)2C receptor inverse agonist and α2-adrenoceptor antagonist that also possesses 5-HT2A antagonist properties that displays a functional profile consistent with improved mood and cognitive performance, together with satisfactory tolerance.

The Serotonin 2C Receptor Antagonist SB 242084 Exhibits Abuse-Related Effects Typical of Stimulants in Squirrel Monkeys

These studies are the first to assess the direct reinforcing effects of a 5-HT2CR-selective antagonist in any species and suggest that SB 242084 exhibits a behavioral profile that is qualitatively similar to other psychostimulants, although its efficacy is modest compared with cocaine.

Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression

6z is a novel 5-HT3 receptor antagonist with potential antidepressant-like activities, which may be related to modulating hypothalamic-pituitary-adrenal axis and attenuating brain oxidative damage.

The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.

Agomelatine behaves as a neutral antagonist at constitutively active h5-HT 2C(INI)Rs and native, cortical 5-HT2CRs and is of interest to determine whether the neutral antagonist properties of agomel atine are related to its favourable clinical profile of antidepressant properties with few side-effects and no discontinuation syndrome.

5-HT2 ligands in the treatment of anxiety and depression

This review synthesizes the current literature about the behavioral, electrophysiological and neurochemical effects of 5-HT2 receptors ligands on the monoaminergic systems but also on adult hippocampal neurogenesis to shed some light on the preclinical evidence supporting the use of 5 -HT2A and/or 5- HT2C receptor antagonists such as antipsychotics, as potential effective adjuncts in SSRIs-resistant depression.

5-HT 2 ligands in the treatment of anxiety and depression

This review synthesizes the current literature about the behavioral, electrophysiological and neurochemical effects of 5-HT2 receptors ligands on the monoaminergic systems but also on adult hippocampal neurogenesis to shed some light on the preclinical evidence supporting the use of 5 -HT2A and/or 5- HT2C receptor antagonists such as antipsychotics, as potential effective adjuncts in SSRIs-resistant depression.

The 5-HT2C Receptor Subtype Controls Central Dopaminergic Systems: Evidence from Electrophysiological and Neurochemical Studies

This chapter was undertaken to summarize the authors’ and others’ works that have extensively explored the role of 5-HT2C receptors in the control of DA systems both in basal and drug-induced conditions, using in vivo electrophysiological and microdialytic techniques.
...

References

SHOWING 1-10 OF 143 REFERENCES

Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.

SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

In contrast to melatonin, agomelatine behaves as an antagonist at 5- HT2B and 5-HT2C receptors: blockade of the latter reinforces frontocortical adrenergic and dopaminergic transmission.

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.

In conclusion, the novel benzodioxopiperazine serotonin (5-HT)1A ligand, S 15535, represents a promising candidate for the treatment of anxious states in man and displays antiaggressive (and antidepressant, accompanying paper) properties.

5-HT2A and 5-HT2C receptors and their atypical regulation properties.

5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.

The results suggest that 5-HT2C receptor agonism is associated with therapeutic potential in obsessive compulsive disorder and depression.

Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents

The results demonstrate that the novel 5-HT2C receptor agonist WAY-163909 produces rapid onset antidepressant-like effects in animal models and may be a novel treatment for depression.
...